Generate Biomedicines: Frances Arnold plans 1,000-share sale

Generate Biomedicines, Inc. (GENB) has a notice of proposed sale on file under Rule 144 for common stock held for the account of Frances Arnold.

Rhea-AI Filing Summary

Generate Biomedicines, Inc. (GENB) has a notice of proposed sale on file under Rule 144 for common stock held for the account of Frances Arnold. The filing indicates that 1,000 shares of common stock are planned to be sold through Fidelity Brokerage Services LLC on or about September 1, 2026. These shares were originally acquired on September 23, 2020 as restricted stock vesting from the issuer as compensation.

Key Figures

Shares of common stock to be sold: 1,000 shares Planned sale date: 09/01/2026 Acquisition date of restricted stock: 09/23/2020

3 metrics

Shares of common stock to be sold 1,000 shares Planned Rule 144 sale for the account of Frances Arnold

Planned sale date 09/01/2026 Indicated date of sale for the 1,000 GENB shares

Acquisition date of restricted stock 09/23/2020 Date the 1,000 GENB shares vested as restricted stock compensation

Key Terms

Rule 144, restricted stock vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Common | 09/23/2020 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Frances Arnold"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing for GENB disclose about Frances Arnold's planned sale?

The Form 144 for GENB discloses that 1,000 shares of Generate Biomedicines common stock held for the account of Frances Arnold are planned to be sold through Fidelity Brokerage Services LLC, with an indicated sale date of September 1, 2026.

How many GENB shares are covered by this Form 144 notice?

The notice covers 1,000 shares of Generate Biomedicines, Inc. common stock to be sold for the account of Frances Arnold under Rule 144.

When were the GENB shares in this Form 144 originally acquired?

The 1,000 GENB shares were originally acquired on September 23, 2020 as restricted stock vesting from Generate Biomedicines, Inc. as compensation.

Who is the broker handling the planned Rule 144 sale for GENB shares?

The planned sale of GENB common stock is listed as being handled by Fidelity Brokerage Services LLC as the broker for the transaction under Rule 144.

On which exchange are the GENB shares in this Form 144 expected to be sold?

The Form 144 indicates that the 1,000 shares of Generate Biomedicines common stock are expected to be sold on NASDAQ.

What is the nature of the GENB securities being sold under this Form 144?

The securities are common stock of Generate Biomedicines, Inc., originally received as restricted stock vesting from the issuer as compensation, and now noticed for potential resale under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:27 PM Accepted by SEC EDGAR 09/01/2026 - 04:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001665419
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Generate Biomedicines, Inc.
SEC File Number	001-43165
Address of Issuer	101 SOUTH STREET, SUITE 900 SOMERVILLE MASSACHUSETTS 02143
Phone	888-469-0055
Name of Person for Whose Account the Securities are To Be Sold	ARNOLD FRANCES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1000	16002.00	128352436	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/23/2020	Restricted Stock Vesting	Issuer			1000	09/23/2020	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Frances Arnold
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)